Adam Cutler Sells 7,148 Shares of Mural Oncology (NASDAQ:MURA) Stock

Mural Oncology PLC (NASDAQ:MURA) CFO Adam Cutler sold 7,148 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $2.09, for a total value of $14,939.32. Following the completion of the sale, the chief financial officer directly owned 99,290 shares of the company’s stock, valued at approximately $207,516.10. This trade represents a 6.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Mural Oncology Stock Performance

Shares of MURA stock traded up $0.01 during trading on Monday, hitting $2.10. 71,743 shares of the company were exchanged, compared to its average volume of 1,520,206. The firm has a market capitalization of $36.41 million, a price-to-earnings ratio of -0.30 and a beta of 2.93. The business’s 50-day simple moving average is $2.08 and its 200 day simple moving average is $2.29. Mural Oncology PLC has a twelve month low of $0.95 and a twelve month high of $4.74.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.38. On average, equities analysts forecast that Mural Oncology PLC will post -7.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on MURA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mural Oncology in a research note on Friday, October 31st. Wall Street Zen cut shares of Mural Oncology from a “hold” rating to a “strong sell” rating in a research note on Sunday, August 10th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $12.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Concurrent Investment Advisors LLC acquired a new stake in shares of Mural Oncology during the 1st quarter worth about $28,000. Quadrature Capital Ltd acquired a new position in Mural Oncology in the second quarter worth $98,000. Rangeley Capital LLC bought a new stake in shares of Mural Oncology during the second quarter worth $115,000. BML Capital Management LLC acquired a new stake in shares of Mural Oncology in the third quarter valued at $119,000. Finally, F m Investments LLC acquired a new stake in shares of Mural Oncology in the second quarter valued at $192,000. 80.21% of the stock is owned by institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.